(VIANEWS) – TINC (TINC.BR), ESSILORLUXOTTICA (EL.PA), VINCI (DG.PA) are the highest payout ratio stocks on this list.
We have congregated information regarding stocks with the highest payout ratio so far. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. TINC (TINC.BR)
69.23% Payout Ratio
TINC Comm. VA is an investment firm specializing in investments in public and private infrastructure, real assets, and energy sector. TINC Comm. VA is based in Antwerpen, Belgium.
Earnings Per Share
As for profitability, TINC has a trailing twelve months EPS of €0.78.
PE Ratio
TINC has a trailing twelve months price to earnings ratio of 15.06. Meaning, the purchaser of the share is investing €15.06 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.13%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 89.6%, now sitting on 58.93M for the twelve trailing months.
Yearly Top and Bottom Value
TINC’s stock is valued at €11.75 at 17:10 EST, under its 52-week low of €11.85.
Volume
Today’s last reported volume for TINC is 1741 which is 89.51% below its average volume of 16606.
More news about TINC.
2. ESSILORLUXOTTICA (EL.PA)
51.97% Payout Ratio
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €4.83.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 35.02. Meaning, the purchaser of the share is investing €35.02 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 22, 2023, the estimated forward annual dividend rate is 3.23 and the estimated forward annual dividend yield is 1.75%.
More news about ESSILORLUXOTTICA.
3. VINCI (DG.PA)
43.51% Payout Ratio
VINCI SA, together with its subsidiaries, engages in concessions, energy, and construction businesses worldwide. Its Concessions segment designs, finances, builds, and operates transport infrastructures and public equipment under public-private partnerships. The company's Energy segment provides services to the manufacturing sector, infrastructure, facilities management, and information and communication technology; and industrial and energy-related services, which includes development of renewable energy concession assets, as well as engineering, procurement, and construction projects in the energy sector. Its Construction segment engages in designing and carrying out projects, which includes general contractor; geotechnical and structural engineering and related digital activities, as well as provision of services in nuclear engineering; proximity networks with active local companies, such as building, civil engineering, roadworks, rail works, and water works; property development, including residential and commercial properties; and management of serviced residences and property services. VINCI SA was founded in 1899 and is headquartered in Nanterre, France.
Earnings Per Share
As for profitability, VINCI has a trailing twelve months EPS of €7.47.
PE Ratio
VINCI has a trailing twelve months price to earnings ratio of 13.86. Meaning, the purchaser of the share is investing €13.86 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.3%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 23.5%, now sitting on 62.51B for the twelve trailing months.
Moving Average
VINCI’s value is under its 50-day moving average of €108.71 and higher than its 200-day moving average of €100.64.
Volume
Today’s last reported volume for VINCI is 146343 which is 82.63% below its average volume of 842775.
More news about VINCI.
4. TUBIZE-FIN (TUB.BR)
39.2% Payout Ratio
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.91.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 36.23. Meaning, the purchaser of the share is investing €36.23 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.93%.
More news about TUBIZE-FIN.
